Department of Molecular and Cell Biology, University of California, Berkeley, California, USA.
Division of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Hum Gene Ther. 2020 May;31(9-10):499-511. doi: 10.1089/hum.2020.069.
Recombinant adeno-associated virus has emerged as one of the most promising gene therapy delivery vectors. Development of these vectors took advantage of key features of the wild-type adeno-associated virus (AAV), enabled by basic studies of the underlying biology and requirements for transcription, replication, and packaging of the viral genome. Each step in generating and utilizing viral vectors involves numerous molecular interactions that together determine the efficiency of vector production and gene delivery. Once delivered into the cell, interactions with host proteins will determine the fate of the viral genome, and these will impact the intended goal of gene delivery. Here, we provide an overview of known interactions of the AAV genome with viral and cellular proteins involved in its amplification, packaging, and expression. Further appreciation of how the AAV genome interacts with host factors will enhance how this simple virus can be harnessed for an array of vector purposes that benefit human health.
重组腺相关病毒已成为最有前途的基因治疗载体之一。这些载体的开发利用了野生型腺相关病毒(AAV)的关键特性,这得益于对病毒基因组转录、复制和包装的基础生物学和要求的基础研究。生成和利用病毒载体的每一步都涉及许多分子相互作用,这些相互作用共同决定了载体生产和基因传递的效率。一旦进入细胞,与宿主蛋白的相互作用将决定病毒基因组的命运,这将影响基因传递的预期目标。在这里,我们概述了 AAV 基因组与参与其扩增、包装和表达的病毒和细胞蛋白的已知相互作用。进一步了解 AAV 基因组如何与宿主因子相互作用,将增强我们对这种简单病毒的利用,以实现一系列有益于人类健康的载体目的。